Rigel Announces Tavalisse(TM) as Proprietary Name for Fostamatinib in the United States

SOUTH SAN FRANCISCO, Calif., April 27, 2017 -- (Healthcare Sales & Marketing Network) -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the U.S. Food and Drug Administration (FDA) has conditionally accepted the proprietary name Tavalisse™... Biopharmaceuticals, Oncology Rigel Pharmaceuticals, Tavalisse, fostamatinib, immune thrombocytopenia
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news